Products for Research Use Only

Mitiglinide-d8 (calcium hydrate)

CAT: 0804-HY-B0682SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0682SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mitiglinide-d8 calcium hydrate (KAD-1229-d8) is the deuterium labeled Mitiglinide calcium hydrate. Mitiglinide calcium hydrate (KAD-1229), an insulinotropic agent, is an ATP-sensitive K+ (KATP) channel antagonist. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel) . Mitiglinide Calcium hydrate can be used for the research of type 2 diabetes[1][2].
UNSPSC
12352005
Target
Potassium Channel
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Solubility
10 mM in DMSO
Smiles
[2H]C1=C(C(C([2H])([C@@]([2H])(CC(N2C[C@@]3([C@]([H])(C2)CCCC3)[H])=O)C([O-])=O)[2H])=C(C([2H])=C1[2H])[2H])[2H].O.[0.5Ca2+]
Molecular Formula
C19H18D8CaNO4-
Molecular Weight
380.54
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Y Sunaga, et al. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431 (1) :119-25.|[3]Kiyoshi Ichikawa, et al. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. May-Jun 2002;29 (5-6) :423-7.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported